Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
![](https://investorshub.advfn.com/uicon/45965.png?cb=1637315758)
Monday, October 04, 2010 2:04:42 PM
Since the mid-1990s the SCID-hu Thy/Liv mouse model has been the standard for HIV testing specifically because it is such an accurate predictor for human testing. The CDC, NIH and FDA all recognize the SCID-hu Thy/Liv murine as an accurate predictor as a test subject pre-clinical work. For a drug such as HIV-Cide, a drug that sweeps HIV particles in the blood, the model is an even more accurate indicator for viral load reduction, which was reported as functionally zero. Moreover, the model excellently represents impact on CD-4 and CD-8 cells, which again were reported as having viral matter reduction following HIC-Cide treatment.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC163193/
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000655
Similarly, the AG129 model for Dengue has been in use since 1998 and over the past 7 years has demonstrated close parallels to human reactions and outcomes to Dengue infections. Again, it is an excellent predictor for humans and all four Dengue types. The problem with Dengue isn't that the mouse models are inaccurate; it's that the vaccines are unstable in the field. So, in the lab all is fine, but start producing thousands of doses for clinical field work and that is when the Dengue vaccine issues begin to show, issues completely unrelated to mouse/human testing.
http://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2009.05057.x/pdf
Herpes virus testing and Hep C also have accurate murine models. The Hep C mouse model has been in use since 2006, while the HSV mouse model has been around about 10 years longer. Although neither have established standard mouse strains for testing, those in use yield data that closely characterize expected human results.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1610068/
http://www.ncbi.nlm.nih.gov/pubmed/1664131
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM